Courtès Marie-Gabrielle, Kountouri Melpomeni, Wang Wenwen, Tille Jean-Christophe, Petignat Patrick, Undurraga Manuela, Labidi-Galy S Intidhar
Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Division of Oncology, Centre Hospitalier du Valais Romand (CHVR), Valais, Switzerland.
Gynecol Oncol Rep. 2024 Apr 14;53:101394. doi: 10.1016/j.gore.2024.101394. eCollection 2024 Jun.
Clear cell carcinoma is a rare and very aggressive subset of cervical cancer, with poor outcome if diagnosed at advanced stage. There are few data available on the optimal management of this histotype, and treatment recommendations that include surgery and chemoradiotherapy, are essentially based on those for squamous cell carcinoma. Here we report the case of a young patient newly diagnosed with advanced stage (FIGO IIB) clear cell carcinoma of the uterine cervix who received a window of opportunity one injection of nivolumab followed by standard chemoradiotherapy. She showed a persistent complete remission after 28 months of follow-up, but developed hypothyroidism, as a consequence of immunotherapy, and required lifelong thyroid hormone replacement.
透明细胞癌是宫颈癌中一种罕见且侵袭性很强的亚型,如果在晚期被诊断出来,预后很差。关于这种组织学类型的最佳治疗方案,可用数据很少,包括手术和放化疗在内的治疗建议基本上是基于鳞状细胞癌的治疗建议。在此,我们报告一例新诊断为晚期(国际妇产科联盟IIB期)子宫颈透明细胞癌的年轻患者的病例,该患者接受了一次纳武单抗注射作为“机会窗”治疗,随后接受了标准的放化疗。经过28个月的随访,她持续完全缓解,但因免疫治疗出现了甲状腺功能减退,需要终身进行甲状腺激素替代治疗。